54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics

Key Takeaways Explain This Topic AI

Obesity classification utilizes Body Mass Index (BMI): Overweight 25.0-29.9 kg/m2, Class I Obesity 30.0-34.9 kg/m2, Class II Obesity 35.0-39.9 kg/m2, and Class III / Severe Obesity >=40.0 kg/m2; in Asian populations, risk-adjusted cutoffs are lower (Overweight >=23.0 kg/m2, Obesity >=27.5 kg/m2) due to higher body fat percentage and visceral adiposity at lower BMI values.

Intensive lifestyle modification targeting a 5% to 10% total body weight loss through a 500-750 kcal/day caloric deficit and >=150-300 minutes/week of moderate-intensity physical activity achieves clinically meaningful improvements in glycemic control, systolic blood pressure, serum triglycerides, and obstructive sleep apnea severity.

FDA-approved anti-obesity medications are indicated for individuals with BMI >=30 kg/m2 or BMI >=27 kg/m2 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea); tirzepatide (dual GIP/GLP-1 receptor agonist, up to ~21% weight reduction) and semaglutide 2.4 mg (GLP-1 receptor agonist, ~15% weight reduction with a 20% reduction in major adverse cardiovascular events demonstrated in the SELECT trial) represent the most potent medical therapies.

The 2022 ASMBS/IFSO guidelines recommend metabolic and bariatric surgery for individuals with BMI >=35 kg/m2 regardless of the presence, absence, or severity of comorbidities, and for individuals with BMI 30.0-34.9 kg/m2 who do not achieve substantial or durable weight loss or comorbidity improvement using nonsurgical methods (Asian thresholds: BMI >=27.5 kg/m2).

Post-bariatric primary care requires lifelong surveillance for micronutrient deficiencies (mandating calcium citrate over calcium carbonate due to bypassed gastric acid), clinical distinction between early dumping syndrome (fluid shifts 15-30 minutes postprandial) and late dumping (hyperinsulinemic hypoglycemia 1-3 hours postprandial), and recognition of internal hernia as an acute surgical emergency in Roux-en-Y gastric bypass patients presenting with severe, intermittent, postprandial abdominal pain.

Last updated: September 2026

Epidemiology, Anthropometrics & Obesity Staging

Obesity is a complex, progressive, relapsing chronic neurobehavioral disease characterized by abnormal or excessive adiposity that impairs physical health, psychosocial functioning, and metabolic homeostasis. Rather than a consequence of lifestyle choice, contemporary clinical paradigms recognize obesity as a disease of impaired central energy homeostasis governed by hypothalamic neuroendocrine feedback loops.

Anthropometric Classification & Population-Specific Cutoffs

The standard screening metric for adiposity is the Body Mass Index (BMI) , calculated as weight in kilograms divided by the square of height in meters ( BMI = kg/m 2 \text{BMI} = \text{kg/m}^2 BMI = kg/m 2 ). While universally accessible, BMI does not directly differentiate between lean muscle mass and adipose tissue, nor does it capture anatomical fat distribution. WORLD HEALTH ORGANIZATION & USPSTF BMI CLASSIFICATIONS

• Classification Standard Cutoff (kg/m²) Asian Population Cutoff (kg/m²)
• ═══════════════════════════════════════════════════════════════════════════════════════
• Underweight < 18.5 < 18.5
• Normal Weight 18.5 – 24.9 18.5 – 22.9
• Overweight 25.0 – 29.9 23.0 – 27.4
• Class I Obesity 30.0 – 34.9 27.5 – 32.4
• Class II Obesity 35.0 – 39.9 32.5 – 37.4
• Class III (Severe) ≥ 40.0 ≥ 37.5
• ═══════════════════════════════════════════════════════════════════════════════════════

Important

ASIAN-SPECIFIC PHENOTYPIC ADJUSTMENT Epidemiological studies demonstrate that individuals of South Asian, East Asian, and Southeast Asian descent have a higher percentage of total body fat and significantly greater visceral (intra-abdominal) adipose accumulation at any given BMI compared to individuals of European descent. Consequently, their cardiovascular and metabolic risk accelerates at lower body mass indices. The World Health Organization (WHO) and American Association of Clinical Endocrinology (AACE) mandate lower diagnostic thresholds for Asian individuals: Overweight begins at BMI ≥23.0 kg/m² , and Obesity begins at BMI ≥27.5 kg/m² .

Waist Circumference & Visceral Adiposity

Abdominal visceral adipose tissue lines the mesenteric vasculature and drains directly into the portal vein, releasing non-esterified free fatty acids, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) directly into the liver. This promotes hepatic insulin resistance, hepatic steatosis, and systemic atherogenesis. Waist circumference is an independent biomarker of cardiovascular mortality even in patients with a normal BMI.

Standard Cutoffs for Abdominal Adiposity :

• Men: >102 cm (>40 inches)
• Women: >88 cm (>35 inches)

Asian / South Asian Specific Cutoffs :

• Men: >90 cm (>35.5 inches)
• Women: >80 cm (>31.5 inches)

Measurement Technique: Measured at the midpoint between the top of the iliac crest and the lowest palpable rib margin in the mid-axillary line at the end of normal expiration.

Clinical Staging: The Edmonton Obesity Staging System (EOSS)

Beyond anthropometry, clinical management is guided by disease staging that reflects end-organ damage and functional limitation:

Stage 0 : No apparent obesity-related risk factors (normal blood pressure, normal glucose tolerance, normal lipids), no physical symptoms, no psychological impairment.

Stage 1 : Subclinical risk factors (borderline hypertension, impaired fasting glucose, elevated liver enzymes), mild physical symptoms (dyspnea on heavy exertion).

Stage 2 : Established obesity-related chronic diseases requiring pharmacotherapy (hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, moderate osteoarthritis, reflux esophagitis), moderate physical limitations.

Stage 3 : Significant end-organ damage (myocardial infarction, stroke, heart failure, diabetic nephropathy, severe disabling osteoarthritis), marked psychological distress.

Stage 4 : Severe, end-stage disabilities from obesity-related chronic diseases (severe functional impairment, wheelchair-bound, tracheostomy for severe hypoventilation).

Intensive Lifestyle Modification & Behavioral Therapy

Comprehensive lifestyle intervention forms the foundational substrate upon which all anti-obesity pharmacotherapy and metabolic surgery rest.

Clinically Meaningful Weight Loss Targets

5% Total Body Weight Loss : Produces clinically significant reductions in systolic and diastolic blood pressure (drop of 3–5 mmHg), decreases glycosylated hemoglobin (HbA1c reduction of 0.5–1.0%), lowers serum triglycerides by 20–30%, elevates HDL cholesterol, and reduces intrahepatic lipid content.

10% Total Body Weight Loss : Substantially reduces the severity of obstructive sleep apnea (OSA) (often reducing the Apnea-Hypopnea Index [AHI] by >50%), improves non-alcoholic steatohepatitis (NASH / MASH) histology, reduces symptomatic knee osteoarthritis pain, and can induce remission of early type 2 diabetes.

≥15% Total Body Weight Loss : Frequently produces complete remission of type 2 diabetes of recent onset, marked reduction in cardiovascular events, and resolution of metabolic dysfunction-associated steatohepatitis with fibrosis regression.

Nutritional Prescriptions & Energy Balance

Caloric Deficit : Effective weight loss requires creating a continuous energy deficit of 500 to 750 kcal/day below baseline energy expenditure. This typically correlates with a structured nutritional prescription of:

• 1,200 to 1,500 kcal/day for women
• 1,500 to 1,800 kcal/day for men

Dietary Composition : Evidence indicates that macronutrient composition (low-carbohydrate vs. low-fat vs. Mediterranean diet) is secondary to long-term patient adherence. The Mediterranean dietary pattern (rich in monounsaturated fatty acids, polyphenols, legumes, fish, and whole grains) confers the strongest evidence for long-term reduction in all-cause mortality and major adverse cardiovascular events (MACE).

Physical Activity Guidelines :

Aerobic Exercise : Moderate-intensity physical activity (e.g., brisk walking, cycling) for ≥150 to 300 minutes per week , or vigorous-intensity activity for ≥75 to 150 minutes per week .

Weight Maintenance Target : Preventing weight regain following successful reduction requires higher exercise volumes: 200 to 300 minutes per week .

Resistance Training : Progressive resistance exercises targeting major muscle groups performed on ≥2 non-consecutive days per week is vital to preserve lean fat-free muscle mass and prevent resting metabolic rate (RMR) attenuation during active weight loss.

Cognitive-Behavioral Interventions : High-intensity behavioral therapy includes regular self-monitoring of food intake and body weight (daily to weekly weigh-ins), stimulus control (modifying home/work eating environments), problem-solving skills, and stress reduction strategies.

FDA-Approved Anti-Obesity Medications (AOMs)

Pharmacotherapy is an adjunct to lifestyle modification for long-term weight management. It acts by modulating hypothalamic hunger circuits, gut peptide satiety signaling, or nutrient absorption.

Regulatory Indications & Stopping Rules

Initiation Criteria :

BMI ≥30 kg/m² (regardless of comorbidities), OR

BMI ≥27.0 to 29.9 kg/m² in the presence of at least one weight-related medical condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, non-alcoholic fatty liver disease).

Efficacy Assessment (The 12-Week Stopping Rule) : Anti-obesity medications should be evaluated at 12 to 16 weeks on the maximum tolerated dose . If the patient has not achieved a weight loss of ≥5% of baseline body weight , the medication should be discontinued, as continued efficacy is unlikely, and an alternative agent or surgical referral should be initiated. FDA-APPROVED ANTI-OBESITY MEDICATIONS OVERVIEW

Medication Mechanism of Action Average % Weight Loss Key Adverse Effects & Boxed Warnings

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Tirzepatide Dual GIP / GLP-1 ~15% to 20.9% Nausea, diarrhea, vomiting, constipation;
• (Zepbound) Receptor Agonist Boxed warning: Thyroid C-cell tumors (MTC/MEN2);
• (Subcutaneous weekly) Reduces oral contraceptive bioavailability

• Semaglutide 2.4 mg Selective GLP-1 ~12.4% to 15.0% Nausea, vomiting, diarrhea, cholelithiasis;
• (Wegovy) Receptor Agonist (SELECT trial: 20% MACE Boxed warning: Thyroid C-cell tumors (MTC/MEN2);
• (Subcutaneous weekly) risk reduction) Pancreatitis, acute kidney injury

• Phentermine / Sympathomimetic amine + ~8.6% to 9.3% Paresthesias, insomnia, dysgeusia, tachycardia;
• Topiramate ER GABA/carbonic anhydrase Teratogen (Category X: oral clefts);
• (Qsymia) (Oral daily) Contraindicated: Glaucoma, hyperthyroidism

• Bupropion / DA/NE reuptake inhibitor + ~5.0% to 6.1% Nausea, headache, constipation, insomnia;
• Naltrexone ER Opioid receptor antagonist Boxed warning: Suicidal ideation;
• (Contrave) (Oral twice daily) Contraindicated: Seizure history, opioids, HTN

• Orlistat Pancreatic and gastric ~3.0% to 5.0% Steatorrhea, fecal urgency, oily spotting;
• (Xenical / Alli) lipase inhibitor Fat-soluble vitamin malabsorption (A, D, E, K);
• (Oral TID with meals) Risk of calcium oxalate nephrolithiasis

• Phentermine Noradrenergic ~3.0% to 5.0% Tachycardia, palpitations, insomnia, anxiety;
• monotherapy sympathomimetic amine (Short-term use only: Schedule IV controlled substance;
• (Adipex-P) (Oral daily) ≤ 12 weeks approved) Avoid in CAD, uncontrolled HTN, glaucoma

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

• 1. Incretin Mimetics: GLP-1 and Dual GIP/GLP-1 Receptor Agonists
• Semaglutide 2.4 mg SC Weekly (Wegovy)

Mechanism : Semaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native GLP-1, modified with a C18 fatty diacid chain that enables non-covalent binding to serum albumin, extending its half-life to ~1 week. It crosses the blood-brain barrier at the area postrema and activates pro-opiomelanocortin (POMC) / cocaine- and amphetamine-regulated transcript (CART) neurons in the arcuate nucleus while inhibiting neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, leading to increased satiety and suppressed appetite. Peripherally, it delays gastric emptying.

Clinical Evidence : In the STEP-1 trial , non-diabetic adults with overweight/obesity receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% at 68 weeks compared to 2.4% with placebo. In the landmark SELECT cardiovascular outcome trial (17,604 patients with preexisting cardiovascular disease and overweight/obesity without diabetes), semaglutide 2.4 mg demonstrated a statistically significant 20% relative risk reduction in major adverse cardiovascular events (MACE: CV death, non-fatal myocardial infarction, or non-fatal stroke) .

Dose Titration Schedule : Initiated at 0.25 mg SC weekly for 4 weeks, titrated every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg, up to the maintenance dose of 2.4 mg SC weekly to mitigate gastrointestinal side effects.

Tirzepatide 15 mg SC Weekly (Zepbound)

Mechanism : Tirzepatide is a first-in-class unimolecular dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist . GIP receptor agonism works synergistically with GLP-1 agonism: while both act centrally in the hypothalamus and hindbrain to suppress appetite and food consumption, GIP receptor activation directly enhances insulin sensitivity in subcutaneous adipose tissue, increases lipid buffering capacity, suppresses systemic inflammation, and reduces nausea typically driven by GLP-1 receptors in the area postrema.

Clinical Evidence : In the SURMOUNT-1 trial , adults with obesity treated with tirzepatide 15 mg weekly achieved an unprecedented mean weight reduction of 20.9% (up to 52 lbs) at 72 weeks, with over 36% of participants losing ≥25% of their total body weight.

Dose Titration : Initiated at 2.5 mg SC weekly for 4 weeks, then escalated by 2.5 mg increments every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum maintenance dose of 15 mg SC weekly .

Class Safety, Contraindications & Practice Pearls

Boxed Warning : Both semaglutide and tirzepatide carry a black box warning for the risk of thyroid C-cell tumors . They are strictly contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) .

Pancreatitis & Gallbladder Disease : Increased risk of acute pancreatitis; discontinue permanently if pancreatitis is suspected. Rapid weight loss increases the incidence of acute cholelithiasis and cholecystitis.

Oral Contraceptive Interaction (Tirzepatide) : Tirzepatide delays gastric emptying, transiently decreasing the peak serum concentration and bioavailability of oral contraceptive pills during initiation and each dose escalation. Female patients using oral hormonal contraceptives must add a barrier method of contraception for 4 weeks after initiation and for 4 weeks following each subsequent dose escalation .

2. Phentermine / Topiramate Extended-Release (Qsymia)

Pharmacology : Combines low-dose phentermine (a sympathomimetic amine that stimulates hypothalamic release of norepinephrine, activating beta-2 adrenergic receptors to induce satiety) and extended-release topiramate (a neurotherapeutic agent that potentiates gamma-aminobutyric acid [GABA] activity, blocks voltage-dependent sodium channels, inhibits AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase).

Efficacy : Demonstrates ~8.6% to 9.3% mean weight loss at 1 year in the EQUIP and CONQUER trials.

Dosing & Titration : Starting dose 3.75 mg/23 mg daily x 14 days, titrated to the standard dose of 7.5 mg/46 mg daily. If <3% weight loss at 12 weeks on 7.5/46 mg, titrate to maximum dose 15 mg/92 mg daily (via an intermediate 11.25/69 mg step). Must taper gradually upon discontinuation to avoid precipitating withdrawal seizures.

Boxed Warnings & Contraindications :

Teratogenicity (Pregnancy Category X) : Topiramate is associated with a significantly increased risk of congenital oral clefts (cleft lip/cleft palate) when taken during the first trimester. A negative serum pregnancy test before initiation and monthly pregnancy tests are mandatory , along with effective dual contraception under the FDA REMS program.

Contraindicated in glaucoma (risk of acute angle-closure secondary to ciliochoroidal effusion) and hyperthyroidism .

Avoid within 14 days of Monoamine Oxidase Inhibitors (MAOIs) due to hypertensive crisis risk.

Adverse Effects : Paresthesias (due to carbonic anhydrase inhibition), dysgeusia (metallic taste, especially with carbonated beverages), cognitive slowing ("brain fog"), insomnia, tachycardia, and nephrolithiasis.

3. Bupropion / Naltrexone Extended-Release (Contrave)

Pharmacology : Combines bupropion (an aminoketone norepinephrine and dopamine reuptake inhibitor [NDRI]) and naltrexone (a pure mu-opioid receptor antagonist). Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons to release alpha-melanocyte-stimulating hormone (α-MSH), which activates melanocortin-4 receptors (MC4R) to decrease appetite and increase energy expenditure. Under normal conditions, POMC neurons co-release beta-endorphin, which acts on inhibitory mu-opioid autoreceptors on POMC cells, producing autoinhibition. Naltrexone blocks this inhibitory feedback loop, allowing sustained POMC neuronal firing. In addition, it modulates mesolimbic dopamine reward circuits, reducing hedonic food cravings.

Efficacy : Demonstrates ~5.0% to 6.1% weight loss at 56 weeks in the COR clinical trial program.

Contraindications & Boxed Warnings :

Black Box Warning : Increased risk of suicidal ideation and behaviors in adolescents and young adults (inherited from bupropion's antidepressant classification).

Absolute Contraindications : Uncontrolled hypertension, seizure disorder or conditions predisposing to seizures (e.g., anorexia nervosa, bulimia, abrupt withdrawal from alcohol or benzodiazepines), chronic opioid use or acute opioid withdrawal (naltrexone precipitates severe, immediate acute opioid withdrawal; patients must be opioid-free for at least 7 to 10 days before starting), and concurrent MAOI use.

4. Orlistat (Xenical 120 mg TID; Alli 60 mg TID OTC)

Mechanism : A potent, specific, and reversible inhibitor of gastric and pancreatic lipases within the lumen of the stomach and small intestine. Forms a covalent bond with active serine residues of lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. Reduces systemic dietary fat absorption by approximately 30%.

Clinical Considerations : Produces modest weight loss (~3-5%). Its clinical utility is severely limited by gastrointestinal adverse effects: steatorrhea, oily spotting, flatus with fecal discharge, and fecal urgency . It impairs the absorption of fat-soluble vitamins ( vitamins A, D, E, and K ); patients must take a daily multivitamin containing fat-soluble vitamins at least 2 hours before or 2 hours after taking orlistat (typically at bedtime). It also increases enteric oxalate absorption, elevating the risk of calcium oxalate nephrolithiasis .

Metabolic & Bariatric Surgery

Metabolic and bariatric surgery represents the most effective and durable intervention for severe obesity, achieving substantial weight loss, remission of obesity-related comorbidities, and a reduction in all-cause long-term mortality.

Updated Indications (2022 ASMBS / IFSO Guidelines)

In 2022, the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) released updated evidence-based guidelines replacing the 1991 NIH consensus criteria:

BMI ≥35.0 kg/m² : Metabolic and bariatric surgery is recommended regardless of the presence, absence, or severity of comorbidities .

BMI 30.0 to 34.9 kg/m² : Metabolic and bariatric surgery should be considered in individuals with metabolic diseases (e.g., type 2 diabetes, hypertension, non-alcoholic steatohepatitis, obstructive sleep apnea) who do not achieve substantial or durable weight loss or comorbidity improvement using nonsurgical methods.

Asian Population Adjustments : The BMI thresholds are adjusted downward by 2.5 kg/m²: surgery is recommended for BMI ≥27.5 kg/m² with metabolic disease.

No Upper Age Limit : Older adults (age >65 years) should be assessed based on physiological frailty and operative risk rather than chronological age. COMPARISON OF PRIMARY BARIATRIC SURGICAL PROCEDURES

• Feature Sleeve Gastrectomy (SG) Roux-en-Y Gastric Bypass (RYGB)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Anatomical Mechanism Purely Restrictive Restrictive + Malabsorptive
• (Resection of ~80% of greater (Small gastric pouch ~15-30 mL
• curvature of the stomach) anastomosed to jejunal Roux limb)

• Hormonal Alterations Marked decrease in circulating Elevated GLP-1, PYY; rapid nutrient
• ghrelin (fundus completely resected) delivery to distal ileum

Mean Total Weight Loss ~25% to 30% at 1-2 years ~30% to 35% at 1-2 years

• Impact on GERD Frequently WORSENS or induces de novo SUPERIOR: Drug of choice for severe
• gastroesophageal reflux / esophagitis GERD and Barrett's esophagus

• Technical Complexity Lower; preserves pyloric sphincter; Higher; two anastomoses (gastrojejunostomy
• no bowel transection or anastomosis and jejunojejunostomy); risk of mesenteric defects

• Unique Complications Staple line leak; gastric twist; Marginal ulcer; anastomotic stricture;
• severe reflux requiring RYGB conversion Internal hernia; severe micronutrient deficits

═════════════════════════════════════════════════════════════════════════════════════════════════════════════ ANATOMY OF ROUX-EN-Y GASTRIC BYPASS (RYGB)

• Esophagus
• │
• ▼
• ┌───────────────┐
• │ Gastric Pouch │ (15–30 mL volume)
• └───────┬───────┘
• │ [Gastrojejunal Anastomosis]
• │
• │ Excluded Remnant Stomach
• │ & Duodenum
• │ (Biliopancreatic Limb: Bile & Pancreatic Juice)
• ▼ │
• Roux (Alimentary) Limb │
• (Carries ingested food) ▼
• │ ┌────────┴────────┐
• └──────────────┬──────────┤ Jejunojejunostomy
• ▼ └─────────────────┘
• Common Channel
• (Digestion & Absorption of Nutrients)
• │
• ▼
• Colon
• Post-Bariatric Primary Care Management & Complications

Following bariatric surgery, the primary care physician plays a critical role in monitoring for surgical complications, managing nutritional deficiencies, and preventing weight regain.

1. Lifelong Micronutrient Supplementation

Because of reduced oral intake, decreased hydrochloric acid secretion, and bypass of the duodenum and proximal jejunum (the primary sites for absorption of iron, calcium, and fat-soluble vitamins), post-bariatric patients require dedicated lifelong supplementation:

Calcium Citrate (1,200 to 1,500 mg daily in divided doses) :

Crucial Rule : Calcium citrate MUST be used rather than calcium carbonate. Calcium carbonate requires an acidic gastric environment to dissociate and be absorbed. In post-bariatric anatomy, the diminished parietal cell mass in the gastric pouch yields hypochlorhydria, rendering calcium carbonate largely insoluble and unabsorbable. Calcium citrate is acid-independent.

Must be taken in divided doses (≤500 mg per dose) and separated from iron supplements by at least 2 hours to avoid competitive intestinal transporter inhibition.

Vitamin D3 (Cholecalciferol) : 3,000 IU daily (titrated to serum 25(OH)D ≥30 ng/mL).

Vitamin B12 (Cobalamin) : 350 to 1,000 mcg daily orally (crystalline form absorbed via passive diffusion across distal mucosa) or 1,000 mcg IM monthly. Deficiencies arise from loss of gastric intrinsic factor and diminished peptic cleavage of protein-bound cobalamin.

Elemental Iron (45 to 60 mg daily for RYGB or menstruating women) : Iron is primarily absorbed in the duodenum, which is bypassed in RYGB. Must be co-administered with vitamin C to enhance absorption and taken 2 hours apart from calcium.

Thiamine (Vitamin B1) : 12 to 50 mg daily in standard multivitamins. Any patient presenting with intractable post-bariatric vomiting, hyperemesis, or rapid weight loss must immediately receive parenteral thiamine (500 mg IV TID) prior to any glucose administration to prevent Wernicke encephalopathy (triad of ataxia, ophthalmoplegia, and acute confusion).

2. Dumping Syndromes: Early vs. Late DIFFERENTIAL DIAGNOSIS OF DUMPING SYNDROMES

• Feature Early Dumping Syndrome Late Dumping Syndrome
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Timing Post-Meal 15 to 30 minutes 1 to 3 hours

• Pathophysiology Hyperosmolar chyme rapidly empties into Rapid delivery of simple carbohydrates to
• the jejunum ──► Massive fluid shift the jejunum ──► Rapid glucose absorption ──►
• from intravascular space to bowel lumen Exaggerated GLP-1 & insulin spike ──►
• ──► Splanchnic dilation & hypovolemia Reactive Hyperinsulinemic Hypoglycemia

• Key Symptoms Abdominal cramping, borborygmi, explosive Shakiness, diaphoresis, palpitations,
• diarrhea, nausea, tachycardia, flushing, lightheadedness, hunger, neuroglycopenia
• diaphoresis, dizziness, syncope (confusion, seizures, syncope)

• Diagnostic Test Clinical diagnosis; oral glucose challenge Mixed-meal tolerance test demonstrating
• provokes pulse rise ≥10 bpm at 30 min serum glucose <50 mg/dL with high insulin/C-peptide

• Primary Management • Small, frequent, dry meals • Strict elimination of high-glycemic index foods
• Separate liquids from solids by 30 min • High-protein, high-fiber, complex carb snacks
• Restrict concentrated simple sugars • Second-line pharmacotherapy: Acarbose
• Lie recumbent for 30 min post-meal (alpha-glucosidase inhibitor) or Octreotide
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• 3. Acute and Subacute Postoperative Complications

Anastomotic Leak : Typically presents within the first 10 days postoperatively. Sustained resting tachycardia (>120 beats/min) is the earliest, most reliable, and most sensitive physical sign of a leak , often preceding fever, abdominal tenderness, or leukocytosis. Other signs include tachypnea, left shoulder pain (diaphragmatic irritation), and oliguria. Mandates immediate surgical re-exploration.

Marginal Ulcer : Develops on the jejunal side of the gastrojejunostomy in RYGB due to acid exposure to acid-sensitive jejunal mucosa, ischemia, or foreign body reaction (staples). Presents with epigastric pain, nausea, upper GI bleeding, or perforation. Cigarette smoking and nonsteroidal anti-inflammatory drugs (NSAIDs) are potent causal triggers; both are strictly contraindicated for life in patients with gastric bypass .

Cholelithiasis Prophylaxis : Rapid mobilization of adipose tissue increases biliary cholesterol saturation, causing gallstone formation in up to 30% to 50% of bariatric patients within the first 6 months. Ursodeoxycholic acid (Actigall 300 mg BID or 500 mg daily) administered for 6 months postoperatively reduces the incidence of gallstone formation by >70% .

Internal Hernia (Petersen's Space Hernia) : Unique to Roux-en-Y reconstruction where mesenteric defects created during surgical limb positioning permit small bowel loops to herniate, twist, and strangulate. Can occur months to years postoperatively . Characterized by sudden, severe, crampy mid-abdominal pain that is intermittent, often postprandial, and classically described as a "swirling" or twisting sensation . Physical examination and standard laboratories may be deceptively normal. CT with IV contrast may show mesenteric swirl ("whirl sign"), but a negative CT does NOT rule out internal hernia. Any post-RYGB patient with severe unexplained abdominal pain requires urgent surgical consultation for diagnostic laparoscopy to avoid catastrophic mesenteric infarction.

Loading diagram... Primary Care Algorithm for Evaluation and Management of Post-Bariatric Abdominal Pain